Status:
COMPLETED
6-week Safety and PD Study in Adults With NAFLD
Lead Sponsor:
Pfizer
Conditions:
Non-alcoholic Fatty Liver Disease
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
IN THIS PHASE 2A, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED, 3 ARM, PARALLEL- GROUP STUDY, SAFETY, TOLERABILITY, AND PHARMACODYNAMICS OF PF-06835919 ADMINISTERED ONCE DAILY FOR 6 WEEKS WILL BE ASSE...
Eligibility Criteria
Inclusion
- BMI at least 28 kg/m2
- Type 2 diabetes and/or metabolic syndrome
Exclusion
- Liver disease
- Type 1 diabetes
- Recent heart attack or stroke
- Inability to have an MRI scan
Key Trial Info
Start Date :
September 27 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 27 2018
Estimated Enrollment :
53 Patients enrolled
Trial Details
Trial ID
NCT03256526
Start Date
September 27 2017
End Date
April 27 2018
Last Update
April 4 2019
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
National Research Institute
Los Angeles, California, United States, 90057
2
Avail Clinical Research, LLC
DeLand, Florida, United States, 32720
3
Stand-Up MRI of Miami
Miami, Florida, United States, 33145
4
Avail Clinical Research, LLC
Orange City, Florida, United States, 32763